RxDoctor Payments DataLook up a doctor →

Nicolette Haley

Family · Utica, NYNPI 1801407515

Payments from drug & device makers

$19,023in general payments, 2019–2025

Across 1,037 payments — averaging $18.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$3K
  • AbbVie$3K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Amgen$1K
  • Sun Pharmaceutical Industries Inc.$1K
  • Sanofi$1K
  • plus $8K from 20 others

What the payments were for

  • Food & beverage$17,78193%
  • Education$1,2427%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,023 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$111,594
Medicare patients
643
Services billed
2,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast52$258,048
Skyrizi PenRisankizumab-Rzaa12$245,119
Humira(Cf) PenAdalimumab12$85,564
Cosentyx Sensoready PenSecukinumab13$85,182
Dupixent PenDupilumab18$70,759
Dupixent SyringeDupilumab12$53,765
Pimecrolimus13$4,404
Tacrolimus20$3,723
Clindamycin Phosphate52$3,600
Clobetasol Propionate78$3,127
Metronidazole59$2,959
Betamethasone Dipropionate51$2,215
Triamcinolone Acetonide118$1,270
Ketoconazole52$1,084
Econazole Nitrate16$898

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$1,393$258,04852 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in Utica

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →